Related CAS #
50-10-2 (Br); 14214-84-7 (free base)
Synonym
Oxyphenonium Free Base
IUPAC/Chemical Name
Ethanaminium, 2-((cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methyl-
InChi Key
GFRUPHOKLBPHTQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1
SMILES Code
O=C(OCC[N+](CC)(CC)C)C(O)(C1CCCCC1)C2=CC=CC=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
348.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, Gurusamy KS. Pharmacological interventions for acute pancreatitis. Cochrane Database Syst Rev. 2017 Apr 21;4(4):CD011384. doi: 10.1002/14651858.CD011384.pub2. PMID: 28431202; PMCID: PMC6478067.
2: OXYPHENONIUM bromide. J Am Med Assoc. 1957 Aug 31;164(18):2047-8. PMID: 13462727.
3: FRASER H. Oxyphenonium bromide as a mydriatic. Br J Ophthalmol. 1956 Dec;40(12):751-3. doi: 10.1136/bjo.40.12.751. PMID: 13396161; PMCID: PMC1324738.
4: Feitsma KG. Enantiomers of oxyphenonium bromide. Analytical and pharmacological aspects. Pharm Weekbl Sci. 1988 Oct 14;10(5):221-3. doi: 10.1007/BF01956875. PMID: 3144701.
5: ROPER-HALL MJ. Oxyphenonium as an atropine substitute in ophthalmology. Br J Ophthalmol. 1957 Apr;41(4):238-42. doi: 10.1136/bjo.41.4.238. PMID: 13413139; PMCID: PMC509537.
6: Funasaki N, Kawaguchi R, Ishikawa S, Hada S, Neya S, Katsu T. Quantitative estimation of the bitter taste intensity of oxyphenonium bromide reduced by cyclodextrins from electromotive force measurements. Anal Chem. 1999 May 1;71(9):1733-6. doi: 10.1021/ac981286h. PMID: 21662814.
7: Feitsma KG, Postma DS, Koëter GH, Nossent GD, Brenth BF, de Zeeuw RA. Comparative study of the bronchodilating effects of (-)- and (+)-oxyphenonium bromide. Br J Clin Pharmacol. 1988 Jun;25(6):683-7. doi: 10.1111/j.1365-2125.1988.tb05253.x. PMID: 3144299; PMCID: PMC1386444.
8: Scholtmeijer RJ, van Mastrigt R. The effect of oxyphenonium bromide and oxybutynin hydrochloride on detrusor contractility and reflux in children with vesicoureteral reflux and detrusor instability. J Urol. 1991 Aug;146(2 ( Pt 2)):660-2. doi: 10.1016/s0022-5347(17)37887-4. PMID: 1907331.
9: Pokora J, Kleinrok Z, Chodkowska A, Skrzydło-Radomańska B. Effects of pentagastrin and oxyphenonium on the levels of serotonin and 5-hydroxyindoleacetic acid in different parts of the digestive tract, blood and brain of rats. Acta Physiol Pol. 1984 Jul-Aug;35(4):317-23. PMID: 6085901.
10: LEVINE RM, CLARK BB. The physiological disposition of oxyphenonium bromide (antrenyl) and related compounds. J Pharmacol Exp Ther. 1957 Sep;121(1):63-70. PMID: 13481828.
